BCLI.OB

[saffeysite1]

Brainstorm Cell Therapeutics, Inc. develops NurOwn cell therapy products sourced from adult stem cells for treatment of neurodegenerative diseases. It primarily focuses on the utilization of patients' own bone marrow stem cells to generate neuron-like cells that would provide a treatment for Parkinson's disease, as well as for multiple sclerosis and other neurodegenerative disorders.

Looks like in a new uptrend.  Keep on watch.

[evgeny05]

BrainStorm Makes Progress Towards Human Stem Cell Therapy for Parkinson's -- Animal Model Shows Long-Term Benefit
Business Wire - December 13, 2005 08:30

NEW YORK & TEL AVIV, Israel, Dec 13, 2005 (BUSINESS WIRE) -- BrainStorm Cell Therapeutics (OTCBB:BCLI), the developer of NurOwn(TM) bone marrow derived stem cell therapeutic products for the treatment of Parkinson's and other neurodegenerative diseases, announced today the results of a follow-up preclinical study evaluating the long-term impact of the company's dopaminergic cell treatment for Parkinson's disease.

The results of the study, which was conducted by the Company's scientific collaborators at Tel Aviv University, demonstrate remarkable therapeutic benefit of the Company's human bone marrow stem cell derived NurOwn (TM) cells.

"BrainStorm's success in being able to develop human-derived dopaminergic stem cells that can survive and significantly improve the condition of Parkinson's animal models over a lengthy period of time is a major breakthrough. This exciting finding will pave the way for us to move ahead with plans to apply our therapy to human patients," said Yoram Drucker, Principal Executive Officer of BrainStorm.

The study results demonstrated a more than fifty percent reduction in the animals' rotational movement, seven months after implantation. The study significantly shows superior advantage of the Company's cell differentiation technology over the use of undifferentiated mesenchymal stem cells.

Dr. Daniel Offen, BrainStorm's Chief Scientist observed that, "Unlike competitive approaches that aim to use bone marrow stem cells directly, our therapeutic strategy is based on a unique process for differentiating bone marrow stem cells into neural-like cells capable of secreting dopamine, the substance that is depleted in Parkinson's patients."

"The great improvement in motor function in the Parkinsonian animals after such a long-term treatment with our adult stem cell therapy indicates its highly-promising long-term restorative potential," said Prof. Eldad Melamed, the Company's Chief Medical Advisor and Chairman of its Scientific Advisory Board.

In other studies, Brainstorm has successfully used bone marrow stem cells to produce astrocyte-like cells with the capacity of producing glial derived neurotrophic factor (GDNF). Both dopamine and GDNF producing cells hold great promise for replacement and preservation of neurons in Parkinson's and other neurodegenerative diseases.

Working with human bone marrow stem cells, BrainStorm also has achieved differentiation of human bone marrow stem cells into neural-like cells capable of dopamine secretion.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing neural-like stem cell therapeutic products, NurOwn(TM), based on autologous bone marrow derived stromal cells, for treatment of neurodegenerative diseases. NurOwn(TM) patent pending technology is based on discoveries made by the team of prominent neurologist, Prof. Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research Center of Tel-Aviv University, enabling the differentiation of bone marrow derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University. The company's initial focus is on developing treatments for Parkinson's Disease.

About Stem Cell Therapy

[Ramsburg]

Somebody mentioned BCLI to me this weekend, the volume is still low, but at these price levels should be probably a stock under the radar.

The sector is speculative...

[pompano]

Brainstorm Cell therapeutics recieves independent firm upgrade to 1.20

http://biz.yahoo.com/bw/060828/20060828005351.html?.v=1

[setravis]

"BCLI.OB" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.                      
All history on a stock pick in 1 thread is awesome.                     
Just trying to get threads together,so we don't have a numerous amount floating around on the same stock.
Thank You....and good luck with all your trades....make some $$$       


Friday's closing chart....... "Happy New Year" !

 

[setravis]

Having a brainstorm...


52wk Range: 0.21 - 0.80
Volume: 378,297
Avg Vol (3m): 55,037.5

5W Public Relations to Represent BrainStorm Cell Therapeutics

5W Public Relations, the nation's fastest growing public relations agency in the U.S., announced today that BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI - News), a highly advanced adult stem-cell research firm on the cusp of certain breakthroughs for neurological disorders such as Parkinson's, Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS), has hired the firm as its PR agency of record.

With its cutting edge, non-controversial stem cell research cultivating adult stem cells rather than embryonic tissue, BrainStorm is in advanced testing stages of animal and safety tests for exciting new treatments for Parkinson's Disease and preliminary research in Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease, and its goal is to develop long-term and even permanent remedies for these life-threatening disorders.

By way of BrainStorm's research and treatments, those stricken with these diseases may finally see relief. Investors backing BrainStorm are trading in a company that is developing treatment to save lives, while it also provides an investment option and the potential for financial opportunity.

"5W Public Relations is a firm with unmatched experience in harnessing media and developing unique strategy," said Chaim Lebovits, President of BrainStorm Cell Therapeutics Inc. "With substantial expertise in business media, and in the health and wellness areas, including work within our industry, 5W Public Relations is uniquely qualified to handle this innovative account. With Brainstorm's recent announcement of its $5 million equity financing arrangement, it is now able to accelerate its technology and business development efforts, including partnering with firms such as 5W Public Relations."

About 5W Public Relations

Headquartered in New York, with an office in Los Angeles, 5W Public Relations (www.5wpr.com), the nation's fastest growing independent PR firm for the past three years in a row (2004-2006), maintains practice areas specializing in bio-technology, corporate, health, consumer, entertainment, crisis communications, event management and public affairs. Described by a leading PR trade magazine as "aggressive in a way that clearly resonates with clients looking for a firm staffed with type A-plus personalities, a BS-free approach, and results from Day One," 5W's culture is aggressive, energetic, fast-paced and focused. The agency boasts a diversified client portfolio second to none, including: Evian Natural Spring Water, Anheuser Busch, NICE Systems, Phillips-Van Heusen Corporation, the world's largest shirt and neckwear company, VeriSign, Patina Restaurant Group, the nation's largest multi-concept restaurant group, The Ice Rink at Rockefeller Center, 530 store retail chain United Retail Group/Avenue Stores, Fannie Mae Foundation, Benny Hinn Ministries, The Language Access Network, Zone Chefs, The Pritikin Longevity Center & Spa, celebrities including Pamela Anderson, Snoop Dogg, Ice Cube, Nick Cannon and NBA Star Jalen Rose, a plethora of publicly traded technology companies, and a variety of other global interests, national corporations, high-profile individuals, regional businesses, government agencies and academic institutions. The agency was named "Boutique Agency of The Year" by a leading PR Trade Magazine.